Urology
Do we need repeated CT imaging in uncomplicated blunt renal injuries? Experiences of a high-volume urological trauma center.
12 Jul, 2022 | 11:46h | UTC
Single-arm Study | Extended focal ablation of localized prostate cancer with high-frequency irreversible electroporation.
11 Jul, 2022 | 11:56h | UTCExtended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial – JAMA Surgery (link to abstract – $ for full-text)
Commentary: Novel Focal Therapy Yields Low Rate of Serious Prostate Cancers — Trial’s 6-month rate of 6% was superior to historical control – MedPage Today (free registration required)
Commentary on Twitter
This single-arm objective performance criteria trial indicated excellent efficacy and safety profile of the second-generation high-frequency irreversible electroporation as primary treatment for localized prostate cancer. https://t.co/FheqcxJeA5
— JAMA Surgery (@JAMASurgery) July 7, 2022
RCT | Sacral neuromodulation for neurogenic lower urinary tract dysfunction.
8 Jul, 2022 | 11:47h | UTCSacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction – NEJM Evidence
Commentary on Twitter
Pts with neurogenic lower urinary tract dysfunction had sacral neuromodulators implanted and optimized. They were then randomized to have the device either remain ON or switched OFF for 2 months. The success rate was 76% in the ON group vs 42% in the OFF. https://t.co/dhteW70jXp pic.twitter.com/1c0w8HOMJm
— NEJM Evidence (@NEJMEvidence) July 7, 2022
M-A | It is not safe to withhold antibiotic use in uncomplicated urinary tract infections in adult women.
7 Jul, 2022 | 12:47h | UTC
Commentary on Twitter (thread – click for more)
A really important analysis of previous trials!
1/ All short-term outcomes were worse for women given non-antibiotic strategies, including need for future antibiotics (number needed to harm=5!) https://t.co/iozelljFLk
— Annie Joseph (@ajosephnotts) July 2, 2022
Post-hoc analysis | Can SGLT2 inhibitors reduce the risk of nephrolithiasis?
7 Jul, 2022 | 12:42h | UTC
Consensus Statements | Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in patients with prostate cancer and with respect to [177Lu] Lu-PSMA radioligand therapy.
6 Jul, 2022 | 11:39h | UTCNetwork M-A | High-dose radiotherapy or androgen deprivation therapy as treatment intensification for localized prostate cancer.
6 Jul, 2022 | 11:09h | UTCHigh-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium – European Urology (link to abstract – $ for full-text)
Commentary on Twitter
New In Press: High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortiumhttps://t.co/rZnBjvccNe@AmarUKishan @DrSpratticus et al. pic.twitter.com/uCrg7sRmsS
— European Urology (@EUplatinum) April 25, 2022
RCT | Effect of levofloxacin on the efficacy and adverse events in intravesical Bacillus Calmette-Guerin treatment for bladder cancer.
4 Jul, 2022 | 12:19h | UTCM-A | Antibiotics for preventing recurrent urinary tract infection.
4 Jul, 2022 | 12:17h | UTCOpinion | Renaming Gleason Score 6 prostate to noncancer: a flawed idea scientifically and for patient care.
30 Jun, 2022 | 10:44h | UTCOriginal Opinion Paper: Low-Grade Prostate Cancer: Time to Stop Calling It Cancer – Journal of Clinical Oncology
Study: Biochemical failure is not a surrogate end point for overall survival in recurrent prostate cancer.
28 Jun, 2022 | 10:32h | UTCBiochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 – Journal of Clinical Oncology (link to abstract – $ for full-text)
ASCO Guideline: Management of metastatic clear cell renal cell carcinoma.
22 Jun, 2022 | 11:30h | UTC
Consensus definition and management recommendations: intermediate-risk non–muscle-invasive bladder cancer.
21 Jun, 2022 | 10:52h | UTCIntermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group – European Urology – Oncology (if the link is paywalled, try this one)
Commentary from the author on Twitter
Intermediate-risk NMIBC: Updated Consensus Definition & Management Recs from IBCG (International Bladder Cancer Group)
Full text: https://t.co/QaqGqRN3AE @drtanws @garysteinbergmd @DrShariat @UrogerliMD @MRoupret @spsutkaMD @joanfundi @MarekBabjuk @SWilliams_MD #bladdercancer pic.twitter.com/XQ1sdhqXPZ— Ashish M. Kamat, MD, MBBS (@UroDocAsh) June 17, 2022
The International Penile Prosthesis Implant Consensus Forum: clinical recommendations and surgical principles on the inflatable 3-piece penile prosthesis implant.
21 Jun, 2022 | 10:35h | UTCThe International Penile Prosthesis Implant Consensus Forum: clinical recommendations and surgical principles on the inflatable 3-piece penile prosthesis implant – Nature Reviews Urology (if the link is paywalled, try this one)
RCT: Active surveillance plus Enzalutamide monotherapy vs. active surveillance alone in patients with low-risk or intermediate-risk localized prostate cancer.
21 Jun, 2022 | 10:33h | UTCInvited Commentary: To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer—Weighing the Evidence – JAMA Oncology (free for a limited period)
Video criticizing the article: ENACT trial | A Study That Makes Pharma Rich and Patients’ Poor | I break it down – by Vinay Prasad
Commentaries on Twitter
55% fatigue and 36% gynecomastia. In AS patients.
Why do we keep trying to escalate when the data CLEARLY say we should continue to de-escalate? https://t.co/LY1kD0jN65
— Chris Barbieri (@Chris_Barbieri1) June 17, 2022
The phase 2, open-label ENACT trial compares the efficacy & safety of enzalutamide monotherapy vs active surveillance in patients with low- or intermediate-risk localized #prostatecancer. https://t.co/q9FrL14em1 #PCSM #GUCSM
— JAMA Oncology (@JAMAOnc) June 16, 2022
Single-arm phase 2b study: MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer.
20 Jun, 2022 | 00:56h | UTCMRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In single-arm phase IIb trial of MRI-guided focused ultrasound therapy in 101 men with primary, group 2‒3 intermediate-risk untreated prostate adenocarcinomas, 88% had no evidence of group ≥2 prostate cancer in the treated area at 2 years: https://t.co/xLpqfFm8Ds #PCSM
— NatureRevClinOncol (@NatRevClinOncol) June 16, 2022
Long-term results of RCT: Radiotherapy to the prostate for men with metastatic prostate cancer.
10 Jun, 2022 | 11:10h | UTC
M-A: Adverse cardiovascular events and mortality in men during testosterone treatment.
10 Jun, 2022 | 11:03h | UTCInvited Commentary: Testosterone: therapeutic or toxic for the cardiovascular health of men? – The Lancet Health Longevity
New study associates intake of dairy milk with greater risk of prostate cancer.
10 Jun, 2022 | 10:50h | UTCOriginal Study: Dairy foods, calcium intakes, and risk of incident prostate cancer in Adventist Health Study–2 – American Journal of Clinical Nutrition (link to abstract – $ for full-text)
Circulating tumor DNA as a biomarker in patients with stage III and IV Wilms tumor.
8 Jun, 2022 | 10:43h | UTCCommentary: Analysis of Circulating Tumor DNA as a Biomarker in Stage III and IV Wilms Tumor – The ASCO Post
RCT: Effect of perioperative dexmedetomidine on delayed graft function following a donation-after-cardiac-death kidney transplant.
7 Jun, 2022 | 10:55h | UTC
Commentary on Twitter
In this RCT, 24-hour dexmedetomidine infusion, started immediately after induction of & in addition to standard anesthesia, reduced the incidence of delayed graft function vs placebo, following a donation-after-cardiac-death kidney transplantation. https://t.co/cmX1IEZdVX
— JAMA Network Open (@JAMANetworkOpen) June 3, 2022
Guideline: Evaluation and medical management of the kidney stone patient.
2 Jun, 2022 | 11:02h | UTC
Clinical practice guidelines for penile cancer.
2 Jun, 2022 | 10:57h | UTC
Cohort Study: Taking 5-ARIs for BPH is not associated with increased mortality in prostate cancer.
1 Jun, 2022 | 10:59h | UTCNews Release: Taking 5-ARIs for BPH is not associated with increased mortality in prostate cancer – Karolinska Institute
Original Study: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA Oncology (link to abstract – $ for full-text)
Authors Interview: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA
Commentary: Large study finds no increased risk for prostate cancer death with 5-ARI use – medwire News
Commentary on Twitter
This large population-based cohort study found that men treated with 5α-reductase inhibitors had no increased risk of dying from #prostatecancer, on the contrary indicating a decreased risk with longer treatment duration. https://t.co/y8HlpthNI9 #PCSM #GUCSM
— JAMA Oncology (@JAMAOnc) May 19, 2022
Alcoholic chlorhexidine skin preparation or triclosan-coated sutures to reduce surgical site infection: a systematic review and meta-analysis of high-quality randomized controlled trials.
31 May, 2022 | 11:50h | UTCRelated Study: Reducing surgical site infections in low-income and middle-income countries (FALCON): a pragmatic, multicentre, stratified, randomised controlled trial – The Lancet AND Commentary: Expensive antiseptics and sutures do not reduce the risk of surgical infections – National Institute for Health and Care Research
Commentary from one of the authors on Twitter (thread – click for more)
1. Today: our @TheLancetInfDis meta-analysis based on @FalconRct – triclosan sutures and alcoholic skin prep to reduce surgical site infection.
Link to open access PDF:https://t.co/cj7yFdbNpB pic.twitter.com/VkKRaxCAtm
— Aneel Bhangu (@aneelbhangu) May 27, 2022